1. Home
  2. CII vs SPTX Comparison

CII vs SPTX Comparison

Compare CII & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock Capital and Income Fund Inc.

CII

Blackrock Capital and Income Fund Inc.

HOLD

Current Price

$24.52

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo Seaport Therapeutics Inc. Common Stock

SPTX

Seaport Therapeutics Inc. Common Stock

N/A

Current Price

$21.03

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CII
SPTX
Founded
2004
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2004
2026

Fundamental Metrics

Financial Performance
Metric
CII
SPTX
Price
$24.52
$21.03
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
87.1K
93.1K
Earning Date
01-01-0001
N/A
Dividend Yield
6.17%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.43
$17.59
52 Week High
$26.17
$22.98

Technical Indicators

Market Signals
Indicator
CII
SPTX
Relative Strength Index (RSI) 46.60 50.62
Support Level $23.95 $18.72
Resistance Level $24.45 $22.42
Average True Range (ATR) 0.49 1.41
MACD -0.09 -0.17
Stochastic Oscillator 39.37 24.21

Price Performance

Historical Comparison
CII
SPTX

About CII Blackrock Capital and Income Fund Inc.

Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its investment objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. It may invest directly in such securities or synthetically through the use of derivatives. It also seeks to achieve its investment objective by employing a writing (selling) call and put options.

About SPTX Seaport Therapeutics Inc. Common Stock

Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.

Share on Social Networks: